Search results for "systemic treatment"

showing 8 items of 8 documents

Cancer chemotherapy in the older cancer patient.

2009

This article reviews the principles of systemic cancer treatment in older individuals. These include: assessment of physiologic age with a comprehensive geriatric assessment (CGA), adjustment of chemotherapy doses to the patient's renal function, and prevention of myelotoxicity with hemopoietic growth factors. Other complications that become more common with age include mucositis, peripheral neuropathy and cardiomyopathy. Two chronic complications of chemotherapy become more common with age, including myelodysplasia and chronic cardiomyopathy. The goal of systemic cancer treatment in the older person should include prolongation of active life-expectancy and compression of morbidity in addit…

Nephrologymedicine.medical_specialtyAgingSettore MED/06 - Oncologia MedicaUrologymedicine.medical_treatmentCardiomyopathySystemic treatmentAntineoplastic AgentsKidneyMedical OncologyPatient Care PlanningElderlyLife ExpectancyInternal medicineNeoplasmsmedicineMucositisChemotherapyHumansIntensive care medicineGeriatric AssessmentCancerAgedAged 80 and overChemotherapybusiness.industryKidney metabolismCancermedicine.diseasePeripheral neuropathyTreatment OutcomeOncologyCompression of morbiditybusinessUrologic oncology
researchProduct

Role of thyroid hormones in burning mouth syndrome. Systematic review

2022

Background: Burning mouth syndrome is an idiopathic condition characterized by burning pain in a normalappearing oral mucosa lasting at least four to six months. In the case of secondary burning mouth syndrome is associated with local or systemic factors (such as thyroid disorders) that can cause these symptoms. The aim of this review was to study the relationship between thyroid disorders and burning mouth syndrome. Material and Methods: The present study followed the PRISMA guidelines. An electronic search strategy was developed for PubMed/Medline, Scopus and Cochrane. The following combination of keywords and Boolean operators were used: Thyroid AND burning mouth; Thyroid AND burning mou…

cankerThyroid Hormonestreatmentrecurrent aphtous stomatitisHipertiroïdismeThyrotropinBurning Mouth Syndromesystemic treatmentMalalties de la bocaHyperthyroidismMucosa oralfood supplementstopical treatmentMouth diseasesOtorhinolaryngologyHypothyroidismHumansSurgeryOral mucosaGeneral DentistryUNESCO:CIENCIAS MÉDICAS
researchProduct

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

2022

Treatment for hepatocellular carcinoma (HCC) has experienced major advancements since the last update of the official Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018. Advancements in the field have emerged in all areas, but in this manuscript, we present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need of further research to gain their incorporation into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that is needed to take clinical decisions in individual patients so that the rec…

MaleLiver CancerPrognosis predictionmedicine.medical_specialtyCarcinoma HepatocellularTare weightliver transplantation TACEAFPClinical Trials and Supportive ActivitiesClinical SciencesPsychological interventionSeverity of Illness IndexablationsurvivalArticleTAREsurgeryRare DiseasesClinical ResearchMedicineHepatectomyHumansHCCIntensive care medicineStaging systemNeoplasm StagingCancerHepatologyGastroenterology & Hepatologybusiness.industryLiver DiseaseCarcinomaLiver NeoplasmsALBI scoreHepatocellularsystemic treatmentMiddle Agedmedicine.diseasePrognosisBCLCGood Health and Well BeingHepatocellular carcinomaPublic Health and Health ServicesTreatment strategyFemalebusinessLiver cancerDigestive Diseases
researchProduct

[Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning.]

2014

The aim of this study was to provide practical recommendations for optimizing the use of conventional and biological systemic treatments for moderate-severe chronic plaque psoriasis, particularly in case of transitioning and switching.A total number of 147 dermatologists from 33 different countries including Italy achieved consensus in providing practical recommendations for the use of conventional and biological treatments for moderate to severe psoriasis based on systematic literature review and/or expert opinion.In general, the continuous treatment regimen should be preferred in order to achieve a complete and long-term control of psoriasis. However, the treatment could be stopped or the…

switchingsystemic treatmentssystemic treatments; switching; transitioning; psoriasismoderate-severe chronic plaque psoriasispsoriasistransitioningSettore MED/35 - MALATTIE CUTANEE E VENEREE
researchProduct

Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network

2021

Background: To report on a retrospective case-series analysis of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma treated within the Italian Rare Cancer Network. Methods: Adult patients with a diagnosis of advanced, brachyury-positive chordoma, treated from April 2007 to October 2020 with wCDDP or wCDDP/I were retrospectively identified. Imatinib was withheld at the same time as wCDDP. Response according to Response Evaluation Criteria in Solid Tumors, overall survival (OS), and progression-free survival (PFS) were analyzed. Results: Thirty-three consecutive patients were identified (wCDDP as front-line n = 8 [24.2%]; wCDDP as…

AdultCancer Researchbone sarcomacisplatinsystemic treatmentchemotherapyDisease-Free SurvivalTreatment OutcomeOncologyimatinibImatinib MesylateHumansProspective StudieschordomaRetrospective Studies
researchProduct

Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

2015

SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in…

RegistrieMaletaiwanAntitubercular AgentsBiological Factorquantiferon-tb-goldAntitubercular AgentBiological FactorsexperienceResidence Characteristics80 and overPrevalenceRegistriesYoung adultriskAged 80 and overLatent TuberculosiLatent tuberculosispsoriasisMiddle AgedItalyFemaletubercolosistubercolosiAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young Adult; 2708Humanmedicine.drugAdultmedicine.medical_specialtyAdolescentchronic plaque psoriasisTuberculinconsensus statementtubercolosis; psoriasisDermatology.Young Adulttuberculosis infectionSettore MED/35Age DistributionLatent TuberculosisInternal medicinePsoriasismedicineAdalimumabfactor antagonistsHumansPsoriasisnecrosis-factor blockers; quantiferon-tb-gold; consensus statement; factor antagonists; systemic treatment; therapy; experience;taiwan; assay; risknecrosis-factor blockersSex DistributionAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young AdultPUVA TherapyAgedPsoriasiHistory of tuberculosistherapytuberculosis infection chronic plaque psoriasisItalian Psocare Registrybusiness.industryTuberculin TestOdds ratiosystemic treatmentassaymedicine.diseasebacterial infections and mycosesConfidence intervalSurgeryResidence CharacteristicChronic DiseaseItalian Psocare Registrybusiness2708
researchProduct

Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setti…

2021

Immune checkpoint inhibitors (ICIs) are the new frontier for the treatment of advanced hepatocellular carcinoma (HCC). Since the first trial with tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 inhibitor, increasing evidence has confirmed that these drugs can significantly extend the survival of patients with advanced hepatocellular carcinoma (HCC). As a matter of fact, the overall survival and objective response rates reported in patients with advanced HCC treated with ICIs are the highest ever reported in the second-line setting and, most recently, the combination of the anti-programmed death ligand protein-1 atezolizumab with bevacizumab—an anti-vascular endothelial growth fa…

SorafenibOncologymedicine.medical_specialtyBevacizumabPopulationSystemic treatmentReviewunresectable hepatocellular carcinoma03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinemedicineeducationSettore MED/12 - Gastroenterologiaeducation.field_of_studybusiness.industryRGeneral Medicinemedicine.diseaseUnresectable hepatocel-lular carcinomaRegimenReal-world030220 oncology & carcinogenesisHepatocellular carcinomaMedicine030211 gastroenterology & hepatologyImmunotherapybusinessLiver cancerImmunotherapy; Liver cancer; Real-world; Systemic treatment; Unresectable hepatocel-lular carcinomaLiver cancerTremelimumabmedicine.drugJournal of Clinical Medicine
researchProduct

Buccal drug delivery: what's new and what does the future hold?

2014

The buccal mucosa is the stratified squamous epithelial tissue inside lining of the cheeks. It is a favorable site of drug absorption since the tissue is non-keratinized, relatively immobile and strongly supplied with blood by a dense capillary-vessel network; moreover, it is highly tolerant to allergens, resistant to potentially harmful agents and has a relatively low enzymatic activity. The tissue consents quick onset of effect, offers an easily accessible and generally well-accepted site for drug delivery, is a useful route of administration in patients in an unconscious state (e.g., when swallowing is impaired), and is suitable for retentive dosage forms of administration. Buccal mucosa…

3003Drugmedia_common.quotation_subjectChemistry PharmaceuticalPharmaceutical ScienceDentistryPharmacologyDosage formRoute of administrationDrug Delivery SystemsPharmacokineticsMucositisMedicineAnimalsHumansBuccal dosage formmedia_commonDosage FormsDrug Carriersbusiness.industryLocoregional/systemic treatmentMedicine (all)Mouth MucosaAdministration BuccalTransmucosal deliveryBuccal administrationmedicine.diseaseBioavailabilityPharmaceutical PreparationsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryBuccal mucosaDiffusion of InnovationbusinessForecastingTherapeutic delivery
researchProduct